– The Motley Fool is a financial services company founded in 1993 dedicated to making the world smarter, happier, and richer
– Eli Lilly has seen a surge in revenue due to the success of their weight-loss drugs Mounjaro and Zepbound
– If you had invested $10,000 in Eli Lilly in July 2019, your investment would now be worth over $86,400, a 760% increase
– Demand for weight-loss drugs is expected to grow, with projections indicating a $100 billion market by 2030
– Eli Lilly is continuing to innovate and expand its manufacturing capacity, positioning itself as a top stock for growth
– The company is expected to continue delivering gains and is recommended as a top stock to hold on to today.